Methadone Hydrochloride Dtf 1mg/1ml Oral Solution
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Methadone Hydrochloride DTF 1mg/1ml Oral Solution
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Methadone Hydrochloride BP 5mg/5ml
3. PHARMACEUTICAL FORM
Oral Solution
4. CLINICAL PARTICULARS
4.1. Therapeutic indications
For use in the treatment of opioid drug addictions (as a narcotic abstinence syndrome suppressant).
For use as an analgesic for moderate to severe pain.
4.2. Posology and method of administration
For oral administration only Addiction:
Adults: Initially 10-20mg per day, increasing by 10-20mg per day until
there are no signs of withdrawal or intoxication. The usual dose is 40-60mg per day.
Elderly: In the case of the elderly or ill patients repeated doses should
only be given with extreme caution.
Children: Not recommended for children.
Pain:
Adults: Usual single dose 5 to 10mg orally. Owing to its long plasma
half life, caution with repeated dosage should be observed in the very ill or elderly. The usual initial dose should be 5 to 10mg, 6 to 8 hourly, later adjusted to the degree of pain relief obtained.
Elderly: Use caution with repeated dosage in elderly and ill patients.
Children: Not suitable.
4.3 Contraindications
Respiratory depression, obstructive airways disease. Use during an acute asthma attack is not recommended.
Concurrent administration with MAO inhibitors or within 2 weeks of discontinuation of treatment with them.
Patients dependent on non-opioid drugs.
Use during labour is not recommended, the prolonged duration of action increases the risk of neonatal depression.
Methadone is not suitable for children.
Known hypersensitivity to methadone or any ingredients in the medicine.
Raised intracranial pressure or head injury.
Phaeochromocytoma.
Risk of paralytic ileus (including drug induced gastrointestinal hypotonia).
4.4. Special warnings and precautions for use
Caution should be exercised in patients with hepatic dysfunction or renal dysfunction.
In the case of elderly or ill patients, repeated doses should only be given with extreme caution.
Addiction/Tolerance/Dependence
Methadone is a drug of addiction and is controlled under the Misuse of Drugs Act 1971 (Schedule 2). Methadone has a long half-life and can therefore accumulate. A single dose which will relieve symptoms may, if repeated on a daily basis, lead to accumulation and possibly death.
Tolerance and dependence may occur as with morphine.
Methadone can produce drowsiness and reduce consciousness although tolerance to these effects can occur after repeated use.
Withdrawal
Abrupt cessation of treatment can lead to withdrawal symptoms which, although similar to those with morphine, are less intense but more prolonged. Withdrawal of treatment should therefore be gradual.
Respiratory depression
Due to the slow accumulation of methadone in the tissues, respiratory depression may not be fully apparent for a week or two and may exacerbate asthma due to histamine release.
Hepatic disorders
Caution as methadone may precipitate porto-systemic encephalopathy in patients with severe liver damage.
As with other opioids, methadone may cause troublesome constipation, which is particularly dangerous in patients with severe hepatic impairment, and measures to avoid constipation should be initiated early.
Biliary tract disorders.
Neonates/children
As there is a risk of greater respiratory depression in neonates and because there are currently insufficient published data on the use in children, methadone is not recommended in those under 16 (See sections 4.2, 5.2).
There are reports of neonates exposed to methadone during pregnancy developing visual disorders, in particular, nystagmus. The causal relationship to methadone in isolation has not been established as factors such as other drugs taken during pregnancy e.g. benzodiazepines, intake of alcohol, and drugs used to treat neonatal abstinence syndrome e.g. phenobarbital, could play a role in the adverse reactions seen.
Further warnings
Babies born to mothers receiving methadone may suffer withdrawal symptoms.
Methadone should be used with great caution in patients with acute alcoholism, convulsive disorders and head injuries.
Methadone, as with other opiates, has the potential to increase intracranial pressure especially where it is already raised.
Methadone should be used with caution in patients with hypothyroidism, adrenocortical insufficiency, prostatic hyperplasia, hypotension, shock, inflammatory or obstructive bowel disorders or myasthenia gravis.
Cases of QT interval prolongation and torsades de pointes have been reported during treatment with methadone, particularly at high doses (>100 mg/d). Methadone should be administered with caution to patients at risk for development of prolonged QT interval, e.g. in case of:
- history of cardiac conduction abnormalities,
- advanced heart disease or ischaemic heart disease,
- liver disease,
- family history of sudden death,
- electrolyte abnormalities, i.e. hypokalaemia, hypomagnesaemia
- concomitant treatment with drugs that have a potential for QT-prolongation,
- concomitant treatment with drugs which may cause electrolyte abnormalities,
- concomitant treatment with cytochrome P450 CYP3A4 inhibitors (see section 4.5).
In patients with recognised risk factors for QT-prolongation, or in case of concomitant treatment with drugs that have a potential for QT-prolongation, ECG monitoring is recommended prior to methadone treatment, with a further ECG test at dose stabilisation.
ECG monitoring is recommended, in patients without recognised risk factors for QT-prolongation, before dose titration above 100mg/d and at seven days after titration.
Caution should be exercised in patients who are concurrently taking CNS depressants.
Excipient warnings:
This product contains
■ E102 and E110, which may cause allergic reactions.
■ Liquid maltitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
■ Sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. The product contains 0.9g of sucrose per 5ml and should be taken into account in patients with diabetes mellitus. It may be harmful to teeth.
■ Methyl and Propyl hydroxybenzoates. These may cause allergic reactions (possibly delayed).
4.5 Interaction with other medicinal products and other forms of interaction
MAPI's:
The concurrent use of MAOI’s is contraindicated (see 4.3 Contraindications) as they may prolong and enhance the respiratory depressant effects of methadone.
CNS depressants:
Anaesthetics, hypnotics (including benzodiazepines, chloral hydrate and chlormethiazole), anxiolytics, sedatives, barbiturates, phenothiazines, some other major tranquillizers and tricyclic antidepressants may increase the general depressant effects of methadone when used concomitantly. (See 4.4 Special warnings and precautions for use). Antipsychotics may enhance the sedative effects and hypotensive effects of methadone.
Methadone may increase desimipramine levels by up to a factor of two.
There are reports that antidepressant drugs (e.g. fluvoxamine and fluoxetine) may increase serum levels of methadone.
Alcohol may enhance the sedative and hypotensive effects of methadone and increase respiratory depression.
Histamine ^Antagonists:
Histamine H2 antagonists such as cimetidine, can reduce the protein binding of methadone resulting in increased opiate action.
Antibacterials
Rifampicin: Reduced plasma levels and increased urinary excretion of methadone can occur with concurrent administration of rifampicin. Adjustment of the dose of methadone may be necessary.
Ciprofloxacin: Plasma levels of methadone may increase with concurrent administration of ciprofloxacin due to inhibition of CYP 1A2 and CYP 3A4. Reduced serum concentrations of ciprofloxacin may occur. Concomitant use may lead to sedation, confusion and respiratory depression.
Erythromycin: Theoretically this may increase methadone levels due to decreased methadone metabolism.
Fluconazole and ketoconazole: May raise methadone levels, due to decreased methadone metabolism.
Anticonvulsants (Phenytoin, Phenobarbital, Carbamazepine and Primidone):
Induces the metabolism of methadone and there may be a risk of precipitating withdrawal syndrome. Adjustment of the dose of methadone should be considered.
pH of urine:
Drugs that acidify or alkalinise the urine may have an effect on clearance of methadone as it is increased at acidic pH and decreased at alkaline pH.
Opioid Agonist Analgesics:
Additive CNS depression, respiratory depression and hypotension Opioid antagonists:
Naloxone and naltrexone antagonises the analgesic, CNS and respiratory depressant effects of methadone and can rapidly precipitate withdrawal symptoms (See Section 4.9 Overdose). Similarly buprenorphine and pentazocine may precipitate withdrawal symptoms.
Antiretroviral Agents such as Nevirapine, Efavirenz, Nelfinavir. Ritonavir, Abacavir: Based on the known metabolism of methadone, these agents may decrease plasma concentrations of methadone by increasing its hepatic metabolism._Methadone may increase the plasma concentration of zidovudine. Narcotic withdrawal syndrome has been reported in patients treated with some retroviral agents and methadone concomitantly. Methadone maintained patients beginning antiretroviral therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.
Cyclizine and other sedating antihistamines
May have additive psychoactive effects; antimuscarinic effects at high doses.
Other Drugs:
Methadone may have an effect on other drugs as a consequence of reduced gastrointestinal motility.
Pregnancy Tests:
Methadone may interfere with the urine testing for pregnancy.
Cytochrome P450 3A4 inhibitors:
Methadone clearance is decreased when co-administered with drugs which inhibit CYP3A4 activity, such as some anti-HIV agents, macrolide antibiotics, cimetidine and azole antifungal agents (since the metabolism of methadone is mediated by the CYP3A4 isoenzyme).
St. John’s Wort:
May lower plasma concentrations of methadone.
Grapefruit Juice:
There are several anecdotal reports of raised methadone levels due to decreased methadone metabolism.
Drugs affecting gastric emptying:
Domperidone and metoclopramide may increase the speed of onset but not the extent of methadone absorption by reversing the delayed gastric emptying associated with opioids. Conversely, methadone may antagonise the effect of domperidone/metoclopramide on gastro-intestinal activity.
Antiarrhvthmics:
Methadone delays the absorption of mexiletine.
Methadone and QT interval prolongation
In patients taking drugs affecting cardiac conduction, or drugs which may affect electrolyte balance there is a risk of cardiac events when methadone is taken concurrently. Please refer to Section 4.4.
4.6. Fertility, pregnancy and lactation
There is no evidence of safety in human pregnancy. A careful risk/benefit assessment should be made before administration to pregnant women because of possible adverse effects on the foetus and neonate including respiratory depression, low birth weight, neonatal withdrawal syndrome and increased rate of stillbirths. However, methadone has not been associated with congenital malformations.
It may be necessary to increase the dose of methadone if withdrawal symptoms develop. Increased clearance and reduced plasma levels have been reported during pregnancy.
During labour there is a risk of gastric stasis and inhalation pneumonia in the mother and foetal distress. Methadone should not be used in labour (see 4.3 Contraindications).
Lactation: Methadone is excreted in breast milk. Specialist care for obstetric and paediatric staff with experience in such management is required. If breast feeding is considered, the dose of methadone should be as low as possible and the infant monitored to avoid sedation. Breast-fed infants may develop physical dependence and exhibit withdrawal symptoms.
Reports of visual disorders have been reported in neonates following exposure to methadone during pregnancy. However, other factors have also been present and a definitive causal link to methadone has not been established (see section 4.4).
4.7. Effects on ability to drive and use machines
This may be severely affected during and after treatment with Methadone as it may cause drowsiness and reduce alertness. The time after which such activities may be safely resumed is extremely patient dependant and must be decided by the physician.
This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called ‘statutory defence’) if:
- The medicine has been prescribed to treat a medical or dental problem and
- You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
- It was not affecting your ability to drive safely.
4.8. Undesirable effects
The adverse effects of methadone are generally the same as with other opioids, most commonly nausea and vomiting, which are observed in approximately 20% of the patients who undergo methadone out-patient treatment, where the medicinal control is often unsatisfactory.
The most serious adverse effect of methadone is respiratory depression, which may emerge during the stabilisation phase. Apnoea, shock and cardiac arrest have occurred.
Adverse reactions listed below are classified according to frequency and system organ class. These reactions are more frequently observed in non-opioid-tolerant individuals. Frequency groupings are defined according to the following convention: very common (> 1/10), common (> 1/100 to <1/10), uncommon (> 1/1,000 to < 1/100), rare (> 1/10,000 to < 1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
|
System organ class (MedDRA) |
Frequency |
Adverse event |
|
Blood and lymphatic |
Not known |
Reversible |
|
system disorders |
thrombocytopenia has been reported in opioid-dependent patients with chronic hepatitis. | |
|
Metabolism and nutrition disorders |
Common |
Fluid retention |
|
Not known |
Anorexia, hypokalaemia, hypomagnesaemia | |
|
Psychiatric disorders |
Common |
Euphoria, hallucinations |
|
Uncommon |
Dysphoria, dependence, agitation, insomnia, disorientation, reduced libido | |
|
Nervous system disorders |
Common |
Sedation |
|
Uncommon |
Headache, syncope | |
|
Eye disorders |
Common |
Blurred vision, miosis, dry eyes |
|
Not known |
Nystagmus | |
|
Ear and labyrinth disorders |
Common |
Vertigo |
|
Cardiac disorders |
Rare |
Bradycardia, palpitations, cases of prolonged QT interval and torsade de pointes have been reported, especially with high doses of methadone. |
|
Vascular disorders |
Uncommon |
Facial flush, hypotension |
|
Respiratory, thoracic and mediastinal disorders |
Uncommon |
Pulmonary oedema, exacerbation of asthma, dry nose, respiratory depression particularly with large doses, |
|
Gastrointestinal disorders |
Very common |
Nausea, vomiting |
|
Common |
Constipation | |
|
Uncommon |
Xerostomia, glossitis | |
|
Hepatobiliary disorders |
Uncommon |
Bile duct dyskinesia |
|
Skin and subcutaneous tissue disorders |
Common |
Transient rash, sweating |
|
Uncommon |
Pruritis, urticaria, other rash and in very uncommon cases bleeding urticaria | |
|
Endocrine disorders |
Not known |
Raised prolactin levels with long-term administration |
|
Renal and urinary disorders |
Uncommon |
Urinary retention, antidiuretic effect |
|
Reproductive system and breast disorders |
Uncommon |
Reduced potency, galactorrhoea, dysmenorrhoea and amenorrhoea |
|
General disorders and administration site |
Common |
Fatigue, drowsiness |
|
Uncommon |
Oedema of the lower |
|
conditions |
extremities, asthenia, oedema, hypothermia | |
|
Investigations |
Common |
Weight increase |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
4.9. Overdose
Symptoms:
Serious overdosage is characterised by respiratory depression, extreme somnolence progressing to stupor or coma, maximally constricted pupils, skeletal muscle flaccidity, cold and clammy skin and sometimes bradycardia and hypotension. In severe overdosage, particularly by the intravenous route, apnoea, circulatory collapse, cardiac arrest and death may occur.
Treatment:
A patent airway and assisted or controlled ventilation must be assured. Narcotic antagonists may be required, but it should be remembered that Methadone is a long-acting depressant (36-48 hours) whereas antagonists act for 1-3 hours, so that treatment with the latter must be repeated as needed. An antagonist should not be administered, however, in the absence of clinically significant respiratory or cardiovascular depression. Nalorphine (0.1mg per Kg) or Levallorphan (0.02mg per Kg) should be given intravenously as soon as possible and repeated, if necessary, every 15 minutes.
Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. In a person physically dependent on narcotics, administration of the usual dose of a narcotic antagonist will precipitate an acute withdrawal syndrome; use of the antagonist in such a person should be avoided, if possible, but if it must be used to treat serious respiratory depression it should be administered with great care.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic properties
Methadone is a strong opioid agonist with actions predominantly at the p receptor. The analgesic activity of the racemate is almost entirely due to the 1-isomer, which is at least 10 times more potent as an analgesic than the d-isomer. The d-isomer lacks significant respiratory depressant activity but does have antitussive effects. Methadone also has some agonist actions at the K and 8 opiate receptors. These actions result in analgesia, depression of respiration, suppression of cough, nausea and vomiting (via an effect on the chemoreceptor trigger zone) and constipation. An effect on the nucleus of the oculomotor nerve, and perhaps on opioid receptors in the pupillary muscles causes pupillary constriction. All these effects are reversible by naloxone with pA2 value similar to its antagonism of Morphine. Like many basic drugs, Methadone enters mast cells and releases histamine by a non-immunological mechanism. It causes a dependence syndrome of the Morphine type.
5.2. Pharmacokinetic properties
Methadone is one of the more lipid soluble opioids, and is well absorbed from the gastro-intestinal tract, but undergoes fairly extensive first pass metabolism.
It is bound to albumin and other plasma proteins and to tissue proteins (probably lipoproteins), the concentrations in lung, liver and kidneys being much higher than in blood. The pharmacokinetics of Methadone are unusual, in that there is extensive binding to tissue proteins and fairly slow transfer between some parts of this tissue reservoir and the plasma. With an intramuscular dose of 10mg, a peak plasma concentration of 75pg per litre is reached in one hour. With regular oral doses of 100-120mg daily, plasma concentrations rise from trough levels of approximately 500pg/L to a peak of about 900pg/L in 4 hours.
Marked variations in plasma levels occur in dependent persons on a stable dose of oral Methadone, without any relation to symptoms. Methadone is secreted into sweat and found in saliva and in high concentration in gastric juice. The concentration in cord blood is about half the maternal level.
The half life after a single oral dose is 12-18 (mean 15) hours, partly reflecting distribution into tissue stores, as well as metabolic and renal clearance. With regular doses, the tissue reservoir is already partly filled, and so the half life is extended to 13-47 (mean 25) hours reflecting only clearance. In the first 96 hours after administration, 15-60% can be recovered from the urine, and as the dose is increased so a higher proportion of unchanged Methadone is found there. Acidification of the urine can increase the renal clearance by a factor of at least three and thus appreciably reduce the half time of elimination.
5.3. Preclinical safety data
Not applicable
6. PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Sucrose
Propylene glycol Methyl hydroxybenzoate Propyl hydroxybenzoate Liquid maltitol Tartrazine E102 Sunset yellow E110 Green s E142 Poloxamer 188 Simethicone emulsion 30% Purified water
6.2. Incompatibilities
No major incompatibilities are known
6.3. Shelf life
Amber (type III) glass bottle: 24 months
HDPE bottle: 24 months unopened; 1 month opened
6.4. Special precautions for storage
Store below 25°C but not in a refrigerator, protected from light, under secure conditions as per the Controlled Drugs Regulations.
6.5. Nature and contents of container
Glass bottle pack
Bottle: Amber (type III) glass
Capacities: 100ml or 500ml.
Closure: HDPE, child resistant, tamper evident, EPE wadded closure
Plastic bottle pack
Bottle: HDPE
Capacities: 500ml, 2500ml and 5000ml
Closure: HDPE, child resistant, tamper evident, EPE wadded closure
(for 500ml)
HDPE, LDPE wadded, tamper evident screw cap (for 2500ml and 5000ml)
6.6.
Instruction for use, handling and disposal
None stated
7 MARKETING AUTHORISATION HOLDER
Rosemont Pharmaceuticals Ltd
Rosemont House
Yorkdale Industrial Park
Braithwaite Street
Leeds
LS11 9XE
8. MARKETING AUTHORISATION NUMBER
PL 00427/0086
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
24/10/2008